Shattuck Labs, Inc. (NASDAQ:STTK – Get Free Report) has been assigned a consensus rating of “Buy” from the thirteen analysts that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, nine have given a buy rating and three have issued a strong buy rating on the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $13.70.
A number of research analysts recently issued reports on STTK shares. TD Cowen upgraded Shattuck Labs to a “strong-buy” rating in a research report on Monday, August 24th. UBS Group initiated coverage on Shattuck Labs in a research report on Sunday, October 11th. They issued a “buy” rating and a $17.00 target price on the stock. Needham & Company LLC increased their target price on Shattuck Labs from $17.00 to $19.00 and gave the stock a “buy” rating in a research report on Friday, October 2nd. Wall Street Zen cut Shattuck Labs from a “hold” rating to a “sell” rating in a research note on Saturday, November 7th. Finally, Raymond James Financial reissued a “strong-buy” rating on shares of Shattuck Labs in a report on Thursday, November 5th.
Check Out Our Latest Stock Report on STTK
Institutional Trading of Shattuck Labs
Large investors have recently modified their holdings of the company. BlackRock Inc. bought a new stake in Shattuck Labs in the 2nd quarter valued at about $27,315,000. Frazier Life Sciences Management L.P. bought a new position in Shattuck Labs in the 2nd quarter worth about $26,025,000. State Street Corp grew its position in Shattuck Labs by 67.4% in the 3rd quarter. State Street Corp now owns 3,435,783 shares of the company’s stock worth $23,432,000 after purchasing an additional 1,382,995 shares during the last quarter. Pinnacle Associates Ltd. grew its position in Shattuck Labs by 12.2% in the 3rd quarter. Pinnacle Associates Ltd. now owns 2,099,779 shares of the company’s stock worth $14,320,000 after purchasing an additional 228,337 shares during the last quarter. Finally, Wellington Management Group LLP bought a new position in Shattuck Labs in the 2nd quarter worth about $12,269,000. Institutional investors and hedge funds own 58.74% of the company’s stock.
Shattuck Labs Stock Up 1.8%
STTK opened at $4.55 on Friday. The firm has a market cap of $463.37 million, a price-to-earnings ratio of -8.92 and a beta of 1.21. Shattuck Labs has a fifty-two week low of $1.88 and a fifty-two week high of $8.33. The company’s 50-day moving average price is $5.65 and its 200 day moving average price is $6.05.
Shattuck Labs (NASDAQ:STTK – Get Free Report) last issued its earnings results on Thursday, November 5th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.03). Research analysts anticipate that Shattuck Labs will post -0.51 earnings per share for the current year.
Shattuck Labs Company Profile
Shattuck Labs, Inc. is a clinical-stage biotechnology company developing medicines that modulate the immune system to treat cancer. The company’s research has centered on biologic therapies designed to combine immune checkpoint inhibition with activation of immune cells. Its lead candidate, SL-172154, is an engineered fusion protein designed to block the CD47 “don’t eat me” signal and activate CD40, with the aim of promoting an antitumor immune response. Shattuck has evaluated the candidate in clinical studies for cancers including ovarian cancer and higher-risk myelodysplastic syndromes.
Featured Stories
- Five stocks we like better than Shattuck Labs
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Shattuck Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shattuck Labs and related companies with MarketBeat.com's FREE daily email newsletter.
